Close Menu

NEW YORK (360Dx) – Roche said today it has garnered US Food and Drug Administration approval for its Ventana PD-L1 (SP142) Assay as a companion diagnostic for identifying which triple-negative breast cancer patients have increased PD-L1 expression on tumor-infiltrating immune cells and are more likely to respond to the immunotherapy Tecentriq (atezolizumab) plus chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.